全髋关节置换术后新型口服抗凝药血栓预防优于低分子肝素:瑞典注册研究结果
基于瑞典国家注册数据,纳入2008至2012年因原发性骨关节炎行单侧全髋关节置换术且术后确认使用血栓预防药物的32,663例患者,比较新型口服抗凝药组(5,752例,18%)与低分子肝素组(26,881例,82%)术后3个月内症状性深静脉血栓、肺栓塞及出血、再手术和死亡风险。新型口服抗凝药组症状性深静脉血栓和肺栓塞风险均低于低分子肝素组,出血、再手术和死亡风险两组无差异。
要点
- 新型口服抗凝药组症状性深静脉血栓0.3% vs 低分子肝素组0.6%(OR 0.47,95%CI 0.27-0.76,p=0.026)。
- 新型口服抗凝药组症状性肺栓塞0.1% vs 低分子肝素组0.4%(OR 0.36,95%CI 0.16-0.69,p=0.005)。
- 出血、再手术和死亡风险两组无差异(OR分别为1.03、1.02、0.83)。
核心结论
- 在这项大型注册研究中,新型口服抗凝药与较低的症状性深静脉血栓和症状性肺栓塞风险相关,出血、再手术或死亡风险两组无差异。
- 作者指出,尽管控制了若干潜在混杂变量,但无法确定驱动处方决策的适应证,且两组在血栓预防时长上存在重要差异(新型口服抗凝药术后一般使用时间更长)。
- 作者认为需要未来研究,最好是采用实用性纳入标准的大型随机试验,分析症状性深静脉血栓、症状性肺栓塞和死亡,以确认或反驳本研究发现。
研究设计与样本
- 本研究为基于瑞典国家注册数据的注册研究,证据等级为III级,治疗性研究。
- 2008年至2012年间瑞典共实施78,066例全髋关节置换术,本研究通过合并多个国家注册数据评估了其中32,663例(42%)。
- 纳入患者因原发性骨关节炎行单侧全髋关节置换术,索引手术前5年内无静脉血栓栓塞事件,索引手术前6个月内未处方任何类型强效抗血栓药物,且术后血栓预防通过国家注册中处方药物购买记录确认。
- 队列分为两组:接受新型口服抗凝药者5,752例(18%),接受低分子肝素者26,881例(82%)。
- 主要终点为术后3个月内症状性深静脉血栓和症状性肺栓塞的频率;次要比较为术后3个月内出血(通过诊断编码)、再手术和死亡的组间比较。
主要发现
- 接受新型口服抗凝药组症状性深静脉血栓风险低于接受低分子肝素组(0.3% vs 0.6%,OR 0.47;95%CI 0.27-0.76;p=0.026)。
- 接受新型口服抗凝药组症状性肺栓塞风险低于接受低分子肝素组(0.1% vs 0.4%,OR 0.36;95%CI 0.16-0.69;p=0.005)。
- 两组出血风险无差异(OR 1.03;95%CI 0.82-1.28;p=0.688)。
- 两组再手术风险无差异(OR 1.02;95%CI 0.71-1.44;p=0.860)。
- 两组死亡风险无差异(OR 0.83;95%CI 0.31-1.88;p=0.883)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管控制了若干潜在混杂变量,但无法确定驱动处方决策的适应证。
- 两组在血栓预防时长上存在重要差异(新型口服抗凝药术后一般使用时间更长)。
- 需要未来研究,最好是采用实用性纳入标准的大型随机试验,分析症状性深静脉血栓、症状性肺栓塞和死亡,以确认或反驳本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the use of thromboprophylaxis is well established, there is no consensus on the preferred thromboprophylaxis regimen after THA; large, population-based studies offer an opportunity to examine this problem in a robust way that can complement results from randomized trials. QUESTIONS/PURPOSES: Using data from a large national registry, we asked: (1) Is there any difference between low-molecular weight heparin (LMWH) and new oral anticoagulants in preventing symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), after THA? (2) Are there any differences in safety parameters, such as bleeding, reoperations and mortality, between LMWH and new oral anticoagulants? METHODS: Between 2008 and 2012, 78,066 THAs were performed in Sweden. This study evaluated 32,663 (42%) of them, selected through the merger of several national registries. These patients underwent unilateral THA due to primary osteoarthritis. They had not experienced any venous thromboembolic events 5 years before the index operation and were not prescribed potent antithrombotic agents, of any type, in the 6 months before the index operation. Additionally, their postoperative thromboprophylaxis was confirmed in a national registry by purchase of prescribed medications. We divided the cohort into two groups: those patients who received new oral anticoagulants (5752, 18%) and those who received LMWH (26,881, 82%) as postoperative thromboprophylaxis. Our primary endpoints were the frequencies of symptomatic DVT and symptomatic PE within 3 months of surgery. Our secondary comparison was a between-group comparison of bleeding (by way of diagnostic coding), reoperation, and mortality within 3 months of surgery. Odds ratios (OR) are presented with 95% confidence intervals (CIs) as pooled results for the two groups after adjustment for duration of thromboprophylaxis (short or extended for at least 28 days), year of the index operation, Elixhauser comorbidity index, sex, age and previous treatment with platelet aggregation inhibitors. RESULTS: The risk of symptomatic DVT was lower in the group that received new oral anticoagulants than the group that received LMWH (0.3% versus 0.6%, OR, 0.47; 95% CI, 0.27-0.76; p = 0.026). The risk of symptomatic PE was lower in the group that received new oral anticoagulants than the group that received LMWH (0.1% versus 0.4%, OR, 0.36; 95% CI, 0.16-0.69; p = 0.005). There was no difference in the risk of bleeding (by way of diagnostic coding) (OR, 1.03; 95% CI, 0.82-1.28; p = 0.688), reoperation (OR, 1.02; 95% CI, 0.71-1.44; p = 0.860) or mortality (OR, 0.83; 95% CI, 0.31-1.88; p = 0.883) between groups. CONCLUSIONS: New oral anticoagulants were associated with a lower risk of symptomatic DVT and symptomatic PE in this large, registry study, and we observed no differences in the risk of bleeding, reoperation, or death between the groups. Although we were able to control for a number of potential confounding variables, we cannot ascertain the indications that drove the prescription decisions in this setting, and there were important between-group differences in terms of duration of thromboprophylaxis (new oral anticoagulants generally were used for a longer period of time after surgery). Future studies, preferably large randomized trials with pragmatic inclusion criteria, to analyze symptomatic DVT, symptomatic PE and death are needed to confirm or refute our findings. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Kasina P, Wall A, Lapidus LJ, et al. Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery: Findings from the Swedish Registry. Clin Orthop Relat Res. 2019. PMID: 31136431. doi:10.1097/CORR.0000000000000714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。